- A little-known biotech company has been tapped by the U.S. government to develop an experimental Ebola treatment, signaling a shift toward smaller players in pandemic preparedness.
- The contract, valued at up to $150 million, underscores urgency amid recent outbreaks in Africa.
- Shares of the firm surged over 40% in premarket trading following the announcement.
Emergency Response Deal
The U.S. Department of Health and Human Services has awarded a contract to a small biotech firm, with fewer than 50 employees, to accelerate development of a novel Ebola antiviral. The deal, part of the government's Project BioShield, aims to stockpile the therapy for potential future outbreaks. According to people familiar with the matter, the company’s drug candidate showed promise in early animal studies.
“This is a validation of our platform,” said the company’s CEO in a statement, though he declined to disclose specific trial timelines. The firm, which has yet to bring a product to market, will receive an initial $30 million, with additional payments tied to milestones.
Context and Implications
The award comes as the World Health Organization reports a resurgence of Ebola in Uganda, with a case fatality rate above 50%. Previous outbreaks have relied on treatments from larger players like Regeneron (REGN) and Gilead (GILD). Analysts note that engaging a small firm reflects a broader strategy by the Biomedical Advanced Research and Development Authority (BARDA) to diversify its pipeline.
Shares of the company jumped 42% in early trading, valuing it at roughly $200 million. However, some experts caution that the drug is still in early stages, with human trials not expected to begin until next year. The firm has not yet responded to requests for additional comment.
Update: This article has been corrected to reflect that the contract value is up to $150 million, not $200 million as initially reported.